Stemchymal®[1] is an allogenic stem cell therapeutic derived from the adipose tissue of healthy donors. Mesenchymal stem cells (MSCs) are isolated from the adipose tissue using a propriety cell processing system developed by Steminent Biotherapeutics[2]. The purified MSCs are then administered to patients via Intravenous (IV) infusion.
Stemchymal cell therapy for SCA3
Currently, Stemchymal® is being trailed for the treatment of Spinocerebellar Ataxia 3 (SCA3) a condition characterized by progressive cerebellar ataxia. So far, the treatment has been deemed safe for IV administration. You can discover the main findings from the phase I and phase II trials in our infographic below.
Stemchymal phase I/II clinical trials
In this infographic we have summarized the main findings from the Phase I/II clinical trials of Stemchymal®. We have also provided information on the disease this therapeutic aims to treat, and a timeline of how the drug is progressing clinically in different countries. Inquire now to find out more about our clinical capabilities →
References
- What is Stemchymal® - Steminent Biotherapeutics
- About Steminent - Steminent Biotherapeutics
- Tang et al. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neuro 57:4 (2000)
- Tsai et al. Treatment of Spinocerebellar Ataxia 3 with Mesenchymal Stem Cell treatment Stemchymal. Cell Trans 26 (2017)
Author
Zara Puckrin, BSc
Zara is a GCU graduate who loves minimalism, marketing, and molecular biology. You can contact her on LinkedIn.
Tagged
Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.
